biotech / news / / MarketScreener
Regeneron's Eylea and itepekimab failed to reach the required threshold for statistical significance.
Regeneron's combination therapy failed to achieve statistical significance against Merck's Keytruda in a key trial.
KEY POINTS
- Their planned Eylea pre-filled treatment faces regulatory delays, adding to recent setbacks.
- A new partnership with Parabilis Medicines could involve up to $2.2 billion in milestone payments.
- Analysts warn that repeated failures heighten pressure on Regeneron's late-stage pipeline in the next 12–18 months.
- Regeneron will pursue another trial comparing their therapy to Bristol Myers Squibb's Opdualag despite increased caution.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →